Popular Articles

Senate Begins Debate On Sotomayor's Supreme Court Confirmation
The Senate on Tuesday began its floor debate on the confirmation of Supreme Court nominee Sonia Sotomayor, the Wall Street Journal reports (Bravin, Wall Street Journal, 8/4). The debate will continue for the rest of the week before a final floor vote is held Thursday or Friday (Oliphant/Savage, Los Angeles Times, 8/5). Twenty-eight Republicans have said they will oppose her nomination. As of Tuesday, six Republicans were undecided (Stern, CQ Today, 8/4). In addition, at least six Republicans plan to vote for Sotomayor"s confirmation, while none of the 60 Democrats in the Senate have come out against her.Senate Judiciary Committee ranking member Jeff Sessions (R-Ala.), who has announced his opposition, said, "I have expressed the view since this process began that we are at a fork in the road," asking, "Will we continue to adhere to the classical idea of American jurisprudence? Or will we follow results-oriented judging in which judges cease to be committed to equal justice?" He also said that "certain aspects of her record troubled me, ... whether she is deeply committed to the ideal of objectivity and impartiality" (Los Angeles Times, 8/5). Sotomayor opponent Sen. James Inhofe (R-Okla.) expressed concern about Sotomayor"s statement in a speech that "a wise Latina woman with the richness of her experience would more often than not reach a better conclusion" than a white male judge. Inhofe said, "Well, that"s pretty emphatic. There"s no other way you can interpret that," adding, "She thinks a woman with her experience can make a better conclusion than a white male," and "to me, I consider that racist" (CQ Today, 8/4).However, Sotomayor supporter Sen. Patrick Leahy (D-Vt.) said, "Those who struggle to pin the label of judicial activist on Judge Sotomayor are met by her solid record of judging based on the law." He added, "She is a restrained, experienced and thoughtful judge who has shown no biases in her rulings." Sen. Dianne Feinstein (D-Calif.) said, "You can"t find a nominee with better experience than Judge Sotomayor. She has seen the law from all sides." Sen. Robert Menendez (D-N.J.) said, "When Judge Sotomayor takes her seat at the Supreme Court, America will have come of age" (Los Angeles Times, 8/4).

Babies Born To Native High-Altitude Mothers Have Decreased Risk Of Low Birth Weight
Pregnant women who are indigenous to the Andes Mountains deliver more blood and oxygen to their fetuses at high altitude than do women of European descent. The study helps explain why babies of Andean descent born at high altitude weigh more than European babies born at altitude.
News of the day
Budget: Government Priority On Health Supported, New Zealand Medical Association
The New Zealand Medical Association (NZMA) welcomed today"s Budget which reaffirms the Government"s commitment to solving our long term health workforce problems.
Public Health

Clinipace To Manage Two Phase II Clinical Trials For Inspire Pharmaceuticals

Clinipace, a digital clinical research organization, announced that Inspire Pharmaceuticals, Inc. has selected the company to manage and deploy two phase II studies for the ophthalmic prescription medicine, AzaSite®. Currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial conjunctivitis, Inspire has initiated two Phase II randomized placebo-controlled clinical trials of AzaSite as a potential treatment of blepharitis, an ocular disease characterized by the inflammation of the eyelids. Clinipace will provide technology-driven clinical trial services to Inspire including data management (EDC), clinical monitoring, site management, regulatory document management, and biostatistical consulting. To bring increased trial visibility, the project team will utilize TEMPOTM for Clinical Trials software from Clinipace to manage site initiation, patient enrollment and randomization, clinical data capture, monitoring trip reports, site management, regulatory document tracking, and much more. "We share a common goal with Clinipace of changing the way we approach the clinical development process - shifting away from some of the more traditional CRO processes and moving towards an integrated technology-driven model," said Chad Ice, senior director, clinical research, Inspire. "With Clinipace, we plan to remove unnecessary layers of management and processes," said Ice. "We believe that Clinipace can help assure that communication with our clinical sites is much more seamless - one of the most vital links driving the success of our clinical trial process." "We"re hearing from the market time and time again that pharmaceutical companies are tired of having over-scaled and over-priced res pitched to them from CROs today," said Christopher Porter, chief operating officer, Clinipace. "That"s the driving force behind our dedication to providing innovative companies like Inspire a scalable solution with the right kind and quantity of res to match any size clinical study and operational approach." Clinipace


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):